This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BIOR Biora Therapeutics (BIOR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesTrendsBuy This Stock About Biora Therapeutics Stock (NASDAQ:BIOR) 30 days 90 days 365 days Advanced Chart Get Biora Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.14▼$0.1552-Week Range N/AVolume16,292 shsAverage Volume86,634 shsMarket Capitalization$660 thousandP/E RatioN/ADividend YieldN/APrice Target$23.00Consensus RatingBuy Company Overview Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. Read More Biora Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreBIOR MarketRank™: Biora Therapeutics scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBiora Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiora Therapeutics has received no research coverage in the past 90 days.Read more about Biora Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biora Therapeutics are expected to grow in the coming year, from ($12.66) to ($7.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biora Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biora Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Biora Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BIOR. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiora Therapeutics does not currently pay a dividend.Dividend GrowthBiora Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for BIOR. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for BIOR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biora Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders51.08% of the stock of Biora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.74% of the stock of Biora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biora Therapeutics' insider trading history. Receive BIOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOR Stock News HeadlinesBIORQ Biora Therapeutics, Inc.May 31, 2025 | seekingalpha.comBiora Therapeutics, Inc. (BIORQ)May 13, 2025 | ca.finance.yahoo.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 25 at 2:00 AM | Brownstone Research (Ad)TRexBio Expands Leadership Team with Appointments of Ariella Kelman, M.D., as Chief Medical Officer and Brandon Hants, MBA, as Chief Financial OfficerApril 8, 2025 | finance.yahoo.comBiora Therapeutics Successfully Completes Restructuring ProcessMarch 31, 2025 | markets.businessinsider.comNektar Therapeutics announces senior leadership changeFebruary 5, 2025 | msn.comFirm Retention Summary: Biora TherapeuticsJanuary 13, 2025 | wsj.comBiora Therapeutics undertakes Chapter 11 sales processDecember 31, 2024 | finance.yahoo.comSee More Headlines BIOR Stock Analysis - Frequently Asked Questions How were Biora Therapeutics' earnings last quarter? Biora Therapeutics, Inc. (NASDAQ:BIOR) released its earnings results on Wednesday, November, 10th. The company reported ($4.60) earnings per share for the quarter, topping the consensus estimate of ($4.70) by $0.10. The business had revenue of $0.18 million for the quarter, compared to analysts' expectations of $11.10 million. When did Biora Therapeutics' stock split? Biora Therapeutics's stock reverse split on Tuesday, January 3rd 2023.The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Biora Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biora Therapeutics investors own include AMC Entertainment (AMC), Digital World Acquisition (DWAC), NIO (NIO), Meta Platforms (META), NVIDIA (NVDA), Bank of America (BAC) and Ford Motor (F). Company Calendar Last Earnings11/10/2021Today7/25/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BIOR CIK1580063 Webwww.bioratherapeutics.com Phone833-727-2841FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Price Target for Biora Therapeutics$23.00 High Price Target$23.00 Low Price Target$23.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($13.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$124.11 million Net MarginsN/A Pretax Margin-4,005.83% Return on EquityN/A Return on Assets-332.47% Debt Debt-to-Equity RatioN/A Current Ratio0.05 Quick Ratio0.05 Sales & Book Value Annual Sales$892 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($36.43) per share Price / BookN/AMiscellaneous Outstanding Shares4,523,000Free Float2,213,000Market Cap$660 thousand OptionableOptionable Beta1.12 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:BIOR) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.